Expert Insights on Mastering Hyperkalaemia Management to Improve CKD Outcomes
Released On
May 6, 2025
Expires On
May 5, 2026
Media Type
Internet
Completion Time
1h 20 minutes
Specialty
Nephrology
Topics
Hyperkalemia
This activity is supported by an independent educational grant from AstraZeneca.
This module is not accredited.
Target Audience
This activity is intended for an international audience of nephrologists and other healthcare professionals involved in the management of CKD.
Program Overview
Join leading nephrology experts for a dynamic podcast series exploring practical, evidence-based approaches to managing hyperkalaemia and optimising RAAS inhibitor (RAASi) therapy in patients with chronic kidney disease (CKD). Building on discussions from the WCN 2025 symposium, this series features three concise 20-minute episodes packed with real-world clinical insights, audience-inspired questions, and practical solutions for overcoming treatment barriers.
Listeners will gain expert perspectives on:
- Monitoring potassium levels and applying guideline-based RAASi strategies
- Optimising the use of potassium binders to enable sustained RAASi use
- Managing hyperkalaemia in settings where newer binders are not available
Each episode is designed to deliver actionable takeaways for clinical practice, helping healthcare professionals enhance patient outcomes in diverse care settings.
Learning Objectives
Upon completion of this educational activity, learners will be better able to:
- Describe evidence-based GDMT approaches to optimise RAASi therapy and improve outcomes in patients with CKD with chronic and recurrent hyperkalaemia
- Evaluate the role of potassium binders in managing hyperkalaemia and supporting the continuation of RAASi therapy
- Apply evidence-based approaches to safely and effectively manage potassium levels in patients with CKD
Faculty
James Burton
Professor James Burton is Honorary Consultant Nephrologist, Professor of Renal Medicine and Associate Dean for Clinical Research at the University of Leicester. His principal research interests are the mechanisms underlying uraemic cardiovascular disease modification of cardiovascular risk in patients with end-stage renal disease and the identification and application of novel biomarkers. In addition, Prof Burton is involved in the development and running of clinical trials; he is Chief Investigator for the National Institute for Health and Care Research (NIHR)-funded NightLife trial, which is investigating the impact of nocturnal dialysis on patient outcomes, as well as the Kidney Research UK-funded CONFIRM study, which is exploring the utility of a novel cardiac magnetic resonance imaging technique in patients on haemodialysis. Prof Burton is the independent Chair of two multicentre NIHR Trial Steering Committees and sits on several others. He is the current Chair of the UK Kidney Association Clinical Guidelines Committee and has himself chaired a number of UK guideline updates, making sure that research translates into clinical practice.
Roberto Pecoits Filho
Dr. Roberto Pecoits-Filho is a nephrologist and researcher recognized for his contributions to kidney health. He has served as the Distinguished Clinician Scientist at the Arbor Research Collaborative for Health since 2017 and leads the DOPPS Program Area in Michigan, USA. Additionally, Dr. Pecoits-Filho is an Emeritus Professor of Medicine at the Pontifical Catholic University of Paraná in Brazil. After obtaining his medical degree from the Pontifical Catholic University of Paraná in 1993, Dr. Pecoits-Filho trained in internal medicine and nephrology, completing a fellowship at the University of Missouri. He later earned a PhD in Health Sciences (Clinical Research) from the University of São Paulo. His international exposure includes tenures as a visiting scholar at the Karolinska Institute in Sweden and the George Clinical for Global Health in Australia. Throughout his career, Dr. Pecoits-Filho has been actively involved with the International Society of Nephrology (ISN), contributing in various capacities, from chairing the Young Nephrologists Committee to leading the Education Committee and serving on the ISN Council (as a Latin America Representative) and Executive Committee. His international outreach includes roles such as an ISN Education Ambassador in Malawi and leadership in an ISN Sister Renal Center in Sudan.
Magdalena Madero
Magdalena Madero, MD, is a Professor of Medicine and the Chief of Nephrology at the National Heart Institute in Mexico City. She was trained in Internal Medicine at St Elisabeth’s Medical Center in Boston, MA, and then underwent her nephrology training at Tufts Medical Center, also in Boston, MA. She went back to Mexico City in 2007 where she joined the nephrology staff at the National Heart Institute and became the Head of the Nephrology Division in 2011. Dr Madero's research interests include CKD progression, complications and outcomes, CKD of unknown origin and haemodialysis. She has over 120 publications and more than 7200 citations. She was awarded the Miguel Aleman award in 2015, which is given to the most outstanding young researcher in the country. As part of her educational activities, she runs the largest renal fellowship programmes in the country at the National Heart Institute (affiliated to the main National Mexican University) in addition to teaching the nephrology course at the undergraduate Panamericana University medical school. Dr Madero was the former President of one of the Mexican Societies of Nephrology and served as International Editor for the American Journal of Kidney Diseases (2016–2021) and as a member of the Kidney Disease: Improving Global Outcomes Executive Committee (2018–2021). She served as the Chair for the International Society of Nephrology for Latin America and the Caribbean (2019–2023) and for the International Society of Peritoneal Dialysis (2022–2024). She is also part of the incoming editorial team for the Journal of the American Society of Nephrology as an associate editor (2024–2029).
Navdeep Tangri
Navdeep Tangri is an associate professor in the Division of Nephrology, Department of Medicine and Community Health Sciences, at the University of Manitoba, where he obtained his medical degree. He also serves as an attending nephrologist at Seven Oaks General Hospital, Winnipeg. Dr Tangri’s main research interest revolves around improving clinical decision-making for patients with advanced CKD. His efforts in understanding CKD led to the development of the Kidney Failure Risk Equation (KFRE), which is used worldwide to predict the need for dialysis in patients with CKD. He is presently engaged in multiple validation and implementation exercises to increase the uptake of the KFRE. In addition, Dr Tangri is conducting a large prospective study on physical and cognitive function in patients with advanced CKD, as well as comparative effectiveness studies and clinical trials on the safety and effectiveness of medical therapies in this population. He has active grants from the Canadian Institutes of Health Research (CIHR), the Kidney Foundation of Canada and the National Institutes of Health. Dr Tangri has been the recipient of numerous awards, including the CIHR New Investigator Award and a CIHR foundation award for his work on CKD progression. He is a member of the editorial board of the American Journal of Kidney Disease, the Clinical Journal of the American Society of Nephrology and the Canadian Journal of Kidney Health and Disease, as well as Section Editor for the Epidemiology and Prevention Issue of Current Opinion in Nephrology and Hypertension. He has published over 270 manuscripts and presented at multiple national and international scientific meetings.
Accreditation Statement
This activity is not certified for continuing education credit.
Credit Designation
This activity is not certified for continuing education credit.
Disclosures of Conflicts Of Interest
James Burton
Received consultancy fee for providing speaker services to AstraZeneca, Bayer, Boehringer Ingelheim and Eli Lilly Alliance, and Menarini. Received an independent research grant from Yakult Honsha.
Navdeep Tangri
Received consultancy fee for providing speaker services to AstraZeneca, Bayer, Boehringer Ingelheim, GSK, Janssen Pharmaceuticals, Otsuka Pharmaceuticals, ProKidney and Roche.
Magdelena Madero
Received consultancy fee for attending advisory board for Amgen and Boehringer Ingelheim.
Received consultancy fee for providing speaker services to AstraZeneca.
Roberto Pecoits-Filho
Received consultancy fee for providing speaker services to AstraZeneca, Boehringer Ingelheim and Novo Nordisk.
Instructions for Participation and Credit
This activity is not certified for continuing education credit.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labelled for use in certain jurisdictions. Faculty members have been advised to disclose to the audience any reference to unlabelled or investigational use. No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in these materials. No responsibility is taken for errors or omissions in these materials. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.
Disclaimer
The participants of this educational activity have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information and comparison with recommendations of other authorities.
The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of Nexus Healthcare Education or any of its supporters. The information provided in this activity has been confirmed as medically accurate at the date of publication.
Contact Information
For any questions questions please contact [email protected].